



gp 1646 #11/a
PATENT Dmw
2-6-03

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Castillo et al. Examiner: Chernyshev, O.
Serial No.: 09/938,275 Group Art Unit: 1646
Filing Date: 08/22/2001 Attorney Docket No.: PROTEO.P03
Title of Invention: Therapeutic Applications of Laminin and Laminin-Derived Protein Fragments

Seattle, Washington 98109
January 22, 2003

TO THE COMMISSIONER FOR PATENTS
Washington, D.C. 20231

RECEIVED

FEB 03 2003

RESPONSE TO NOTICE TO COMPLY

TECH CENTER 1600/2900

Applicant acknowledges receipt of a Notice to Comply dated 12/23/2002. A copy of the Notice to Comply form is enclosed herewith as required. Applicant responds to the Examiner's concerns as follows:

The sequence found in Figure 10 of the application is a known sequence (mouse laminin A chain) and therefore it is believed that a new Sequence ID listing is not required. Enclosed is a substitute Figure 10 with the amendment of "Sequence ID No. 12", the new Sequence ID added, as suggested by the Examiner.

✓ Please also amend Page 14, beginning at line 20 of the Specification, Brief Description of the Drawings (see substitute page attached), by inserting -(Seq. ID 12)- immediately after the words "FIGURE 10".

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D. C. 20231.

January 22, 2003

Patrick Dwyer

1-8PCRT.INS

Applicant believes it has responded fully to all of the Examiner's concerns. If the Examiner has any further concerns, Applicant urges him to call Applicant's attorney Patrick Dwyer at (206) 343-7074.


Respectfully submitted,



PATRICK MICHAEL DWYER
Reg. No. 32,411

Tel. No. (206) 343-7074
P03-COMPLY.RSP

PATRICK M. DWYER
PROTEOTECH, INC.
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109



Alzheimer's disease amyloidosis.

FIGURE 7 is a black and white photograph of laminin digested with V8 protease, separated by SDS-PAGE and following interaction with biotinylated A β (1-40). The smallest fragment of V8-resistant laminin that interacts with A β is a ~55 kilodalton fragment.

FIGURE 8 is a black and white photograph of laminin digested with trypsin, separated by SDS-PAGE and following interaction with biotinylated A β (1-40). The smallest fragment of trypsin-resistant laminin that interacts with A β is a ~30 kilodalton fragment.

FIGURE 9 is a black and white photograph of laminin digested with elastase, separated by SDS-PAGE and following interaction with biotinylated A β (1-40). A ~55 kilodalton laminin fragment (arrow) that binds biotinylated A β was identified and sequenced. Note also the presence of a ~130 kDa fragment (arrowheads) that binds A β following 1.5 hours of elastase digestion (lane 2). Panel A is a ligand blot using biotinylated A β as a probe, whereas panel B is Coomassie blue staining of the same blot in Panel A to locate the specific band(s) for sequencing.

SEQ ID NO: 12
FIGURE 10 (~~Seq ID 12~~) shows the complete amino acid sequence of the mouse laminin A chain. Sequencing of the ~55 kilodalton A β -binding band shown in Figure 9 leads to the identification of an 11 amino acid segment (underline and arrowhead) within the laminin A chain. This A β binding region of laminin is situated within the globular domain repeats of the laminin A chain.

OL
04/03/03

FIGURE 11 shows schematic diagrams of laminin and the newly discovered "A β

Notice to Comply

JAN 30 2003

PATENT & TRADEMARK

Application No.

09/938,275

Examiner

Olga N. Chernyshev

Applicant(s)

CASTILLO ET AL.

Art Unit

1646

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: unidentified sequence in Figure 10

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY